Sclerosis: all 3,103 studies

Page 7 of 32. Open to participants first (314), then studies with results posted, then the rest; newest registration first within each.

• Rapalogues for Autism Phenotype in TSC: A Feasibility StudyCompletedNCT01929642Phase 2Results posted
• A Randomized Trial of Two Formal Group Programs for Multiple SclerosisCompletedNCT01918800Not applicableResults posted
• Measurement of Relaxin Peptide in Multiple Sclerosis (MS)CompletedNCT01909492Results posted
• A Study to Explore the Safety and Tolerability of Acthar in Patients With Amyotrophic Lateral SclerosisCompletedNCT01906658Phase 2Results posted
• Methylphenidate to Improve Balance and Walking in MSCompletedNCT01896700Phase 2/3Results posted
• Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) PatientsCompletedNCT01895335Phase 4Results posted
• Immunosuppression in Amyotrophic Lateral Sclerosis (ALS)CompletedNCT01884571Phase 2Results posted
• Gastroesophageal Reflux Treatment in SclerodermaCompletedNCT01878526Phase 3Results posted
• Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple SclerosisTerminatedNCT01874340Phase 2Results posted
• Safety and Tolerability of Glatiramer AcetateCompletedNCT01874145Phase 3Results posted
• Phase 4 Gastrointestinal Tolerability Study of Dimethyl Fumarate in Patients With Relapsing Forms of Multiple Sclerosis in the United StatesCompletedNCT01873417Phase 4Results posted
• Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Participants With Relapsing Forms of Multiple Sclerosis When Used Concurrently With AvonexCompletedNCT01864148Phase 2Results posted
• Idebenone for Primary Progressive Multiple SclerosisCompletedNCT01854359Phase 1/2Results posted
• Mexiletine in Sporadic Amyotrophic Lateral Sclerosis (SALS)CompletedNCT01849770Phase 2Results posted
• Anesthetic Topical Adhesive (Synera™) to Reduce Injection Pain With Subcutaneous Multiple Sclerosis MedicationsCompletedNCT01834586Phase 4Results posted
• Mexiletine for the Treatment of Muscle Cramps in ALSCompletedNCT01811355Phase 4Results posted
• Clinical Trial Nuedexta in Subjects With ALSCompletedNCT01806857Phase 2Results posted
• Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019TerminatedNCT01797965Phase 3Results posted
• Effectiveness of Ankle Foot Orthoses on Gait in Multiple SclerosisTerminatedNCT01796860Not applicableResults posted
• A Phase 4 Study to Assess the Impact of Patient Support Program on Health Related Quality of Life and Adherence in Subjects With Relapsing-Remitting Multiple Sclerosis Administered Rebif® With the RebiSmart™ DeviceCompletedNCT01791244Phase 4Results posted
• Rasagiline in Subjects With Amyotrophic Lateral Sclerosis (ALS)CompletedNCT01786603Phase 2Results posted
• Gilenya in Amyotrophic Lateral Sclerosis (ALS)CompletedNCT01786174Phase 2Results posted
• Raltegravir (Isentress) Pilot Study in Relapsing Multiple SclerosisCompletedNCT01767701Phase 2Results posted
• Study to Evaluate the Feasibility of [18F]Florbetapir PET for Assessment in MS PatientsCompletedNCT01767493Phase 4Results posted
• Study of Ozanezumab (GSK1223249) Versus Placebo in the Treatment of Amyotrophic Lateral SclerosisCompletedNCT01753076Phase 2Results posted
• A Placebo-controlled Study of Efficacy & Safety of 2 Trough-ranges of Everolimus as Adjunctive Therapy in Patients With Tuberous Sclerosis Complex (TSC) & Refractory Partial-onset SeizuresCompletedNCT01713946Phase 3Results posted
• Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS)CompletedNCT01709149Phase 2Results posted
• The Efficacy, Safety, and Tolerability of Laquinimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)CompletedNCT01707992Phase 3Results posted
• A 3-year Multi-center Study to Describe Changes of OCT Parameters Under Treatment With Gilenya®CompletedNCT01705236Phase 4Results posted
• Belimumab for the Treatment of Diffuse Cutaneous Systemic SclerosisCompletedNCT01670565Phase 2Results posted
• Pharmacokinetics of Vitamin D in Multiple Sclerosis and in HealthCompletedNCT01667796Not applicableResults posted
• Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND)CompletedNCT01665144Phase 3Results posted
• Assessing Tolerability of Avonex Intramuscular InjectionsCompletedNCT01641120Not applicableResults posted
• MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus CopaxoneTerminatedNCT01633112Phase 3Results posted
• Efficacy and Safety Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis PatientsCompletedNCT01628393Phase 2/3Results posted
• Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.CompletedNCT01623596Phase 4Results posted
• Phase 3 Extension Study of Dexpramipexole in ALSTerminatedNCT01622088Phase 3Results posted
• Study of Lisdexamfetamine Sulfate to Treat Cognitive Dysfunction in Multiple SclerosisCompletedNCT01615887Phase 2Results posted
• An Study to Investigate the Efficacy of Delta-9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) in Multiple SclerosisCompletedNCT01610713Phase 3Results posted
• An Investigation of Delta-9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) in Multiple Sclerosis PatientsCompletedNCT01610700Phase 3Results posted
• A Long-term Safety Extension Study of Delta-9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) in Multiple SclerosisCompletedNCT01610687Phase 3Results posted
• Stem Cells in Rapidly Evolving Active Multiple SclerosisCompletedNCT01606215Phase 1/2Results posted
• A Study to Evaluate the Effects of Cannabis Based Medicine in Patients With Pain of Neurological OriginCompletedNCT01606176Phase 3Results posted
• A Study of Sativex in the Treatment of Central Neuropathic Pain Due to Multiple SclerosisCompletedNCT01604265Phase 3Results posted
• Safety and Efficacy Study of OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Neurogenic Detrusor Overactivity (NDO) in Non-Catheterizing Patients With Multiple Sclerosis (MS)CompletedNCT01600716Phase 3Results posted
• A Study to Evaluate the Efficacy of Sativex in Relieving Symptoms of Spasticity Due to Multiple SclerosisCompletedNCT01599234Phase 3Results posted
• Safety and Tolerability Study of MEDI-551, a B-cell Depleting Agent, to Treat Relapsing Forms of Multiple SclerosisCompletedNCT01585766Phase 1Results posted
• An Efficacy, Safety and Tolerability Study of Glatiramer Acetate (GA) 20 mg/0.5 ml New Formulation Administered Daily by Subcutaneous (SC) Injection in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)TerminatedNCT01578785Phase 3Results posted
• A 12 -Month, Open-label, Multi-center Study to Explore the Health Outcomes of FTY720CompletedNCT01578330Phase 4Results posted
• Promoting Physical Activity Behavior in Persons With Multiple SclerosisCompletedNCT01572207Not applicableResults posted
• Comparison of Rituximab Induction Therapy Followed by Glatiramer AcetateCompletedNCT01569451Phase 2Results posted
• Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness for Patients With Systemic Sclerosis With Interstitial Lung DiseaseTerminatedNCT01559129Phase 2Results posted
• IL1-TRAP, Rilonacept, in Systemic SclerosisCompletedNCT01538719Phase 1/2Results posted
• An Open Label, Proof of Concept Study to Evaluate the Effects of Dalfampridine Withdrawal on Gait and Balance Parameters in Subjects With Multiple Sclerosis (MS)CompletedNCT01535664Results posted
• Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg (EPOC)CompletedNCT01534182Phase 4Results posted
• A Study of RoActemra/Actemra (Tocilizumab) Versus Placebo in Patients With Systemic SclerosisCompletedNCT01532869Phase 3Results posted
• Topical Rapamycin to Erase Angiofibromas in TSCCompletedNCT01526356Phase 2Results posted
• Phase Ib Study to Evaluate MOR103 in Multiple SclerosisCompletedNCT01517282Phase 1/2Results posted
• Dietary Supplement of Curcumin in Subjects With Active Relapsing Multiple Sclerosis Treated With Subcutaneous Interferon Beta 1aCompletedNCT01514370Phase 2Results posted
• Disease Control and Safety in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) Switching From Natalizumab to FingolimodTerminatedNCT01499667Phase 3Results posted
• Efficacy of Fingolimod in de Novo Patients Versus Fingolimod in Patients Previously Treated With a First Line Disease Modifying TherapyCompletedNCT01498887Phase 4Results posted
• Safety and Tolerability of Fingolimod in Patients With Relapsing-remitting Multiple SclerosisCompletedNCT01497262Phase 3Results posted
• Effect of Physical ACtivity in Fingolimod Treated patiEnts (PACE) With Relapsing-remitting Multiple SclerosisTerminatedNCT01490840Phase 4Results posted
• Vitamin D Supplementation in Multiple SclerosisCompletedNCT01490502Phase 3Results posted
• Efficacy and Safety of GTR in Comparison to Copaxone®CompletedNCT01489254Phase 3Results posted
• Open-Label Study to Assess the Effect of Long-Term Prolonged-Release Fampridine (BIIB041) on Quality of Life as Reported by Participants With Multiple SclerosisCompletedNCT01480076Phase 4Results posted
• Macitentan for the Treatment of Digital Ulcers in Systemic Sclerosis PatientsTerminatedNCT01474122Phase 3Results posted
• Macitentan for the Treatment of Digital Ulcers in Systemic Sclerosis PatientsCompletedNCT01474109Phase 3Results posted
• An Open-Label Immunogenicity and Pharmacokinetics Study of Daclizumab High Yield Process Prefilled Syringe in Relapsing Remitting Multiple SclerosisCompletedNCT01462318Phase 3Results posted
• Ofatumumab Subcutaneous Administration in Subjects With Relapsing-Remitting Multiple SclerosisCompletedNCT01457924Phase 2Results posted
• The Effect of Natalizumab (Tysabri) on Sexual Dysfunction in Multiple SclerosisCompletedNCT01455220Not applicableResults posted
• Diclofenac Sodium Topical Gel to Reduce Injection Site Discomfort in Patients Taking Glatiramer AcetateCompletedNCT01454791Phase 4Results posted
• Safety and Neuroprotective Effects of Polyphenon E in MS; Phase IITerminatedNCT01451723Phase 2Results posted
• Prospective Randomized Endovascular Therapy in Multiple Sclerosis - PREMiSECompletedNCT01450072Not applicableResults posted
• Dalfampridine for Imbalance in Multiple SclerosisCompletedNCT01444300Phase 2Results posted
• Natalizumab (BG00002, Tysabri) Study in Japanese Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)CompletedNCT01440101Phase 2/3Results posted
• Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With DepressionTerminatedNCT01436643Phase 4Results posted
• A Study to Evaluate the Safety, Tolerability and Efficacy of AIN457 in Patients With Relapsing-remitting Multiple SclerosisCompletedNCT01433250Phase 2Results posted
• A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple SclerosisTerminatedNCT01416181Phase 3Results posted
• Extension Study to Evaluate Safety and Efficacy of Natalizumab in Japanese Participants With Relapsing-Remitting Multiple SclerosisCompletedNCT01416155Phase 2Results posted
• Establish Tolerance In MS With Peptide-Coupled, Peripheral Blood Mononuclear CellsCompletedNCT01414634Phase 1/2Results posted
• A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple SclerosisCompletedNCT01412333Phase 3Results posted
• Exploratory Study of the Safety, Tolerability and Efficacy of Multiple Regimens of Natalizumab in Adult Participants With Relapsing Multiple Sclerosis (MS)CompletedNCT01405820Phase 2Results posted
• Study to Investigate the Immune Response to Influenza Vaccine in Patients With Multiple Sclerosis on TeriflunomideCompletedNCT01403376Phase 2Results posted
• Alemtuzumab on Surrogate Markers of Disease Activity and Repair Using Advanced MRI Measures in Subjects With Relapsing Remitting Multiple SclerosisCompletedNCT01395316Phase 4Results posted
• Safety and Efficacy Study of Autologous Bone Marrow Derived Stem Cell Treatment in Amyotrophic Lateral SclerosisCompletedNCT01363401Phase 1/2Results posted
• A Placebo Controlled Trial of Dalfampridine ER for Ambulatory Activity in People With Multiple SclerosisCompletedNCT01356940Phase 4Results posted
• Ampyra for Optic Neuritis in Multiple SclerosisCompletedNCT01337986Phase 2/3Results posted
• Fingolimod Versus Interferon Beta 1b in Cognitive SymptomsCompletedNCT01333501Phase 4Results posted
• Long-Term Safety and Efficacy Study of Peginterferon Beta-1aCompletedNCT01332019Phase 3Results posted
• Study of Fampridine-ER Tablets in Patients With Multiple SclerosisCompletedNCT01328379Phase 3Results posted
• Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple SclerosisCompletedNCT01324232Phase 2Results posted
• Patients With Relapse Remitting Multiple Sclerosis (RRMS): Candidates for MS Therapy ChangeCompletedNCT01317004Phase 4Results posted
• Balance Training for People With Multiple Sclerosis Using Nintendo Wii FitCompletedNCT01299025Not applicableResults posted
• Trial of RAD001 and Neurocognition in Tuberous Sclerosis Complex (TSC)CompletedNCT01289912Phase 2Results posted
• Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® TreatmentCompletedNCT01285401Phase 2Results posted
• Phase 3 Study of Dexpramipexole in ALSCompletedNCT01281189Phase 3Results posted
• A Pilot Study of Lithium in Progressive Multiple SclerosisCompletedNCT01259388Phase 1/2Results posted
• Safety and Efficacy Study of Creatine and Tamoxifen in Volunteers With Amyotrophic Lateral Sclerosis (ALS)CompletedNCT01257581Phase 2Results posted
• Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-betaTerminatedNCT01252355Phase 3Results posted

← Sclerosis overview